Top-Navigation

{$labelLanguagenav}

Schriftgrößen-Navigation

Klinische Studien

EMERALD-2

Prüfplancode	ISRCTN	EudraCT	NCT (clinicaltrials.gov)	DRKS
Durvalumab - D910DC00001		2018-004105-85	NCT03847428

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Status: Aktiv

Studienziel / Fragestellung

Diagnose

Hepatozelluläres Karzinom (Leberzellkarzinom)

Studiendesign

Phase III
Multizentrisch
Randomisiert
Dreiarmig
Doppelblind
Placebo-kontrolliert

Intervention

 Arm A: Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
 Arm B: Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
 Arm C: Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)